Arsenal Biosciences, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.arsenalbio.com
Clinical Trials
2
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
Phase 1
Recruiting
- Conditions
- Advanced/Metastatic Clear Cell Renal Cell CarcinomaRecurrence
- Interventions
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Arsenal Biosciences, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT06245915
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸City of Hope, Duarte, California, United States
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
Phase 1
Active, not recruiting
- Conditions
- Ovarian NeoplasmsFallopian Tube NeoplasmsAbdominal NeoplasmRecurrencePeritoneal NeoplasmsNeoplasms, Glandular and EpithelialOvarian DiseasesCarcinoma, Ovarian EpithelialGenital Neoplasm, Female
- Interventions
- First Posted Date
- 2022-11-15
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Arsenal Biosciences, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT05617755
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸U of Colorado Cancer Center - Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸U of Iowa Health Care, Iowa City, Iowa, United States
News
No news found